美国HIV感染者癌症患者免疫标志物与生存:基于人群的登记链接研究
该研究利用美国14个登记处2008-2019年HIV与癌症登记链接数据,分析12 087例HIV感染者中12种常见癌症。Cox回归显示,癌症诊断后CD4计数0-49 cells/mm3者相比200+者,多种癌症特异性死亡风险显著升高,包括前列腺癌和肺癌等非HIV相关肿瘤。
要点
- CD4计数0-49 cells/mm3与多种癌症特异性死亡风险升高相关。
- 非HIV相关肿瘤如前列腺癌和肺癌也显示这种关联。
- 低CD4计数提示免疫控制肿瘤的作用,可能影响预后。
核心结论
- 在HIV感染者癌症患者中,癌症特异性死亡率随CD4计数降低而增加,包括前列腺癌和肺癌等非HIV相关实体瘤。
研究设计与样本
- 基于人群的登记链接研究,链接美国14个登记处2008-2019年HIV和癌症登记数据,纳入12 087例HIV感染者中的12种常见癌症。
主要发现
- CD4计数0-49相比200+ cells/mm3,癌症特异性死亡风险比:非霍奇金淋巴瘤HR=1.82(95% CI=1.30-2.53),前列腺癌HR=3.98(95% CI=1.56-10.15),卡波西肉瘤HR=4.16(95% CI=1.49-11.67),肺癌HR=1.69(95% CI=1.33-2.14),结直肠癌HR=2.79(95% CI=1.58-4.92),肝癌HR=1.44(95% CI=1.01-2.70)。
- 肺癌中CD4计数200+ cells/mm3者3年癌症特异性累积死亡率为52%,0-49者为72%。
临床怎么用
- 对于HIV感染者癌症患者,应关注CD4计数,低CD4计数可能提示癌症特异性死亡风险升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People with human immunodeficiency virus (HIV, PWH) and cancer have greater cancer-specific mortality than patients without HIV, which may reflect effects of immunosuppression. We aimed to describe the associations between low CD4-cell counts and cancer-specific mortality in PWH with cancer. METHODS: We used linked data from HIV and cancer registries to study 12 common cancers in PWH in 14 registries in the United States and Puerto Rico in 2008-2019. We used Cox regression to estimate hazard ratios (HRs) for the association of CD4 counts measured after cancer diagnosis (0-49, 50-99, 100-199, and 200+ CD4 cells/mm3) with cancer-specific mortality, adjusted for demographic and cancer-related factors. We estimated 3-year cancer-specific cumulative mortality using Fine-Gray models. RESULTS: We evaluated 12 087 PWH and cancer (the most common being non-Hodgkin lymphoma [NHL, N = 2311], prostate cancer [N = 1681], and Kaposi sarcoma [KS, N = 1423]). Cancer-specific mortality was significantly greater for individuals with a CD4 count of 0-49 compared with 200+ cells/mm3 for NHL (HR = 1.82, 95% CI = 1.30-2.53), prostate cancer (HR = 3.98, 95% CI = 1.56-10.15), KS (HR = 4.16, 95% CI = 1.49-11.67), lung cancer (HR = 1.69, 95% CI = 1.33-2.14), colorectal cancer (HR = 2.79, 95% CI = 1.58-4.92), and liver cancer (HR = 1.44, 95% CI = 1.01-2.70). For lung cancer, those with a CD4 count of 200+ cells/mm3 had 3-year cancer-specific cumulative mortality of 52% versus 72% for those with a CD4 count of 0-49. CONCLUSIONS: Among PWH with cancer, cancer-specific mortality increased with lower CD4 counts, including for solid tumors not associated with HIV, eg, prostate and lung cancer. These results highlight the role of immunity in control of cancer.
引用
- Haas CB, Shiels MS, Luo Q, et al. Markers of Immune Function and Survival Among Cancer Patients With HIV in the United States: A Population-based Registry Linkage Study. Clin Infect Dis. 2026. PMID: 42213886. doi:10.1093/cid/ciag333
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。